These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37787890)

  • 1. Impact of the US Accelerated Approval for New Anticancer Drugs on Time to Verification of Benefit and Regulatory Approval in the EU and Japan.
    Ito A; Narukawa M
    Ther Innov Regul Sci; 2024 Jan; 58(1):136-142. PubMed ID: 37787890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Clinical Trials for the US Food and Drug Administration Accelerated Approval and Subsequent Confirmatory Trials: Implications for Drug Approval in Japan.
    Mamiya H; Narukawa M
    Biol Pharm Bull; 2024; 47(7):1345-1349. PubMed ID: 39048356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Anticancer Drugs Approved Under the Accelerated Approval Program in the US: Success or Failure in Converting to Regular Approval.
    Oda Y; Narukawa M
    Ther Innov Regul Sci; 2024 Mar; 58(2):387-394. PubMed ID: 38175382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
    Liu ITT; Kesselheim AS; Cliff ERS
    JAMA; 2024 May; 331(17):1471-1479. PubMed ID: 38583175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.
    Hakariya H; Moriarty F; Ozaki A; Mulinari S; Saito H; Tanimoto T
    Clin Transl Sci; 2024 Jul; 17(7):e13879. PubMed ID: 38987923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
    JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021.
    Luo X; Du X; Li Z; Qian F; Yang Y
    Clin Pharmacol Ther; 2023 Jan; 113(1):170-181. PubMed ID: 36151921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
    Vokinger KN; Kesselheim AS; Glaus CEG; Hwang TJ
    JAMA Health Forum; 2022 Aug; 3(8):e222685. PubMed ID: 36200635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
    Naci H; Smalley KR; Kesselheim AS
    JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan.
    Tajima G; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2022 Sep; 47(9):1395-1401. PubMed ID: 35488803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Related to Conversion from Accelerated to Full Approval for Drugs Approved in the United States Between 2000 and 2016.
    Irisawa K; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Jan; 55(1):82-89. PubMed ID: 32602027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
    Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
    BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.